{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:00:04Z","timestamp":1793775604980,"version":"4.6.1"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The association of chronic inflammation with colorectal cancer recurrence and death is not well understood, and data from large well-designed prospective cohorts are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the associations of inflammatory biomarkers with survival among patients with stage III colon cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study was derived from a National Cancer Institute\u2013sponsored adjuvant chemotherapy trial Cancer and Leukemia Group B\/Southwest Oncology Group 80702 (CALGB\/SWOG 80702) conducted between June 22, 2010, and November 20, 2015, with follow-up ending on August 10, 2020. A total of 1494 patients with plasma samples available for inflammatory biomarker assays were included. Data were analyzed from July 29, 2021, to February 27, 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Exposures<\/jats:title><jats:p>Plasma inflammatory biomarkers (interleukin 6 [IL-6], soluble tumor necrosis factor \u03b1 receptor 2 [sTNF-\u03b1R2], and high-sensitivity C-reactive protein [hsCRP]; quintiles) that were assayed 3 to 8 weeks after surgery but before chemotherapy randomization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was disease-free survival, defined as time from randomization to colon cancer recurrence or death from any cause. Secondary outcomes were recurrence-free survival and overall survival. Hazard ratios for the associations of inflammatory biomarkers and survival were estimated via Cox proportional hazards regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1494 patients (median follow-up, 5.9 years [IQR, 4.7-6.1 years]), the median age was 61.3 years (IQR, 54.0-68.8 years), 828 (55.4%) were male, and 327 recurrences, 244 deaths, and 387 events for disease-free survival were observed. Plasma samples were collected at a median of 6.9 weeks (IQR, 5.6-8.1 weeks) after surgery. The median plasma concentration was 3.8 pg\/mL (IQR, 2.3-6.2 pg\/mL) for IL-6, 2.9\u2009\u00d7\u200910<jats:sup>3<\/jats:sup>pg\/mL (IQR, 2.3-3.6\u2009\u00d7\u200910<jats:sup>3<\/jats:sup>pg\/mL) for sTNF-\u03b1R2, and 2.6 mg\/L (IQR, 1.2-5.6 mg\/L) for hsCRP. Compared with patients in the lowest quintile of inflammation, patients in the highest quintile of inflammation had a significantly increased risk of recurrence or death (adjusted hazard ratios for IL-6: 1.52 [95% CI, 1.07-2.14];<jats:italic>P<\/jats:italic>\u2009=\u2009.01 for trend; for sTNF-\u03b1R2: 1.77 [95% CI, 1.23-2.55];<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001 for trend; and for hsCRP: 1.65 [95% CI, 1.17-2.34];<jats:italic>P<\/jats:italic>\u2009=\u2009.006 for trend). Additionally, a significant interaction was not observed between inflammatory biomarkers and celecoxib intervention for disease-free survival. Similar results were observed for recurrence-free survival and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study found that higher inflammation after diagnosis was significantly associated with worse survival outcomes among patients with stage III colon cancer. This finding warrants further investigation to evaluate whether anti-inflammatory interventions may improve colon cancer outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01150045\">NCT01150045<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.6911","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T16:12:46Z","timestamp":1674749566000},"page":"404","source":"Crossref","is-referenced-by-count":52,"title":["Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"En","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shi","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardaman P.","family":"Shergill","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Pritzker School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Couture","sequence":"additional","affiliation":[{"name":"Department of Medicine, H\u00f4tel-Dieu de Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kuebler","sequence":"additional","affiliation":[{"name":"Columbus NCI Community Oncology Research Program, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Illinois CancerCare PC, Peoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha S.","family":"Krishnamurthi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmie","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Brown","sequence":"additional","affiliation":[{"name":"Cancer Metabolism Program, Pennington Biomedical Research Center, Baton Rouge, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Philip","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bette J.","family":"Caan","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Cespedes Feliciano","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Meyerhardt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi220091r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v72.1","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"coi220091r2","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and colon cancer.","volume":"138","author":"Terzic","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"coi220091r3","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/jso.v115.4","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review.","volume":"115","author":"Haram","year":"2017","journal-title":"J Surg Oncol"},{"key":"coi220091r4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijsu.2018.05.030","article-title":"Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis.","volume":"55","author":"Tan","year":"2018","journal-title":"Int J Surg"},{"issue":"7","key":"coi220091r5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/2211-5463.12083","article-title":"Platelet-to-lymphocyte ratio could be a promising prognostic biomarker for survival of colorectal cancer: a systematic review and meta-analysis.","volume":"6","author":"Peng","year":"2016","journal-title":"FEBS Open Bio"},{"key":"coi220091r7","doi-asserted-by":"publisher","DOI":"10.4065\/80.7.923","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"coi220091r8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention.","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"coi220091r9","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-?B signaling in inflammation.","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"coi220091r10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer.","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"coi220091r11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2011.37","article-title":"C-reactive protein in rheumatology: biology and genetics.","volume":"7","author":"Rhodes","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"coi220091r12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595835","article-title":"C-reactive protein and cancer\u2014diagnostic and therapeutic insights.","volume":"11","author":"Hart","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"coi220091r13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/labinvest.2010.199","article-title":"TNFR2 interposes the proliferative and NF-?B\u2013mediated inflammatory response by podocytes to TNF-a.","volume":"91","author":"Bruggeman","year":"2011","journal-title":"Lab Invest"},{"issue":"1","key":"coi220091r14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3810\/pgm.2011.01.2252","article-title":"C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.","volume":"123","author":"Windgassen","year":"2011","journal-title":"Postgrad Med"},{"issue":"13","key":"coi220091r15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial.","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"JAMA"},{"issue":"13","key":"coi220091r16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer.","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"coi220091r17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/nu9040354","article-title":"Comparisons of the postprandial inflammatory and endotoxaemic responses to mixed meals in young and older individuals: a randomised trial.","volume":"9","author":"Milan","year":"2017","journal-title":"Nutrients"},{"issue":"11","key":"coi220091r18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s004640020021","article-title":"Changes in T cell subsets, interleukin-6 and C-reactive protein after laparoscopic and open colorectal resection for malignancy.","volume":"15","author":"Mehigan","year":"2001","journal-title":"Surg Endosc"},{"issue":"6","key":"coi220091r19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s004640090032","article-title":"Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections.","volume":"15","author":"Ordemann","year":"2001","journal-title":"Surg Endosc"},{"issue":"107-108","key":"coi220091r20","first-page":"752","article-title":"Relationship between C-reactive protein levels and wound infections in elective colorectal surgery: C-reactive protein as a predictor for incisional SSI.","volume":"58","author":"Fujii","year":"2011","journal-title":"Hepatogastroenterology"},{"issue":"17","key":"coi220091r21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1289\/ehp.7199","article-title":"Epidemiologic evaluation of measurement data in the presence of detection limits.","volume":"112","author":"Lubin","year":"2004","journal-title":"Environ Health Perspect"},{"issue":"5","key":"coi220091r22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ije\/dyq191","article-title":"The proof and measurement of association between two things.","volume":"39","author":"Spearman","year":"2010","journal-title":"Int J Epidemiol"},{"key":"coi220091r23","doi-asserted-by":"publisher","DOI":"10.2307\/2344317","author":"Peto","year":"1972","journal-title":"J R Stat Soc A"},{"key":"coi220091r24","doi-asserted-by":"publisher","DOI":"10.2307\/2281868","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"coi220091r25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"11","key":"coi220091r26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","article-title":"Simulation study of confounder-selection strategies.","volume":"138","author":"Maldonado","year":"1993","journal-title":"Am J Epidemiol"},{"issue":"1","key":"coi220091r27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/oxfordjournals.aje.a115101","article-title":"The impact of confounder selection criteria on effect estimation.","volume":"129","author":"Mickey","year":"1989","journal-title":"Am J Epidemiol"},{"key":"coi220091r29","doi-asserted-by":"publisher","DOI":"10.2307\/2335876","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"7","key":"coi220091r30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.298.7.754","article-title":"Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.","volume":"298","author":"Meyerhardt","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"coi220091r32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction.","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"coi220091r33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41416-021-01458-y","article-title":"Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.","volume":"125","author":"Hua","year":"2021","journal-title":"Br J Cancer"},{"key":"coi220091r34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0360-y","author":"Varkaris","year":"2019","journal-title":"Br J Cancer"},{"issue":"6","key":"coi220091r35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/1055-9965.EPI-20-1752","article-title":"Levels of inflammation markers are associated with the risk of recurrence and all-cause mortality in patients with colorectal cancer.","volume":"30","author":"Wesselink","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"coi220091r36","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1080\/0284186X.2020.1800086","article-title":"Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer.","volume":"59","author":"Hermunen","year":"2020","journal-title":"Acta Oncol"},{"issue":"6","key":"coi220091r37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/jjco\/hyq010","article-title":"Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer.","volume":"40","author":"Yeh","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"coi220091r38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10434-000-0133-7","article-title":"Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer.","volume":"7","author":"Belluco","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"coi220091r39","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-04-2000","article-title":"Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.","volume":"11","author":"Rich","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi220091r40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/clim.2001.5163","article-title":"Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.","volume":"102","author":"Galizia","year":"2002","journal-title":"Clin Immunol"},{"issue":"4","key":"coi220091r41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/(ISSN)1096-9098","article-title":"Serum interleukin-6 levels reflect the disease status of colorectal cancer.","volume":"83","author":"Chung","year":"2003","journal-title":"J Surg Oncol"},{"issue":"4","key":"coi220091r42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00595-016-1404-7","article-title":"High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.","volume":"47","author":"Hara","year":"2017","journal-title":"Surg Today"},{"issue":"11","key":"coi220091r43","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i11.1639","article-title":"Serum IL-6, TNFa and CRP levels in Greek colorectal cancer patients: prognostic implications.","volume":"11","author":"Nikiteas","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"3","key":"coi220091r44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cam4.2016.5.issue-3","article-title":"Pretreatment serum interleukin-1\u00df, interleukin-6, and tumor necrosis factor-a levels predict the progression of colorectal cancer.","volume":"5","author":"Chang","year":"2016","journal-title":"Cancer Med"},{"issue":"19","key":"coi220091r45","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"issue":"20","key":"coi220091r46","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1056\/NEJMoa032651","article-title":"A comparison of laparoscopically assisted and open colectomy for colon cancer.","volume":"350","author":"Nelson","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"coi220091r47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1155\/2010\/891869","article-title":"Tumor necrosis factor-a is associated with positive lymph node status in patients with recurrence of colorectal cancer\u2014indications for anti\u2013TNF-a agents in cancer treatment.","volume":"33","author":"Grimm","year":"2010","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"10","key":"coi220091r48","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/codi.2014.16.issue-10","article-title":"Is C-reactive protein useful in prognostication for colorectal cancer? a systematic review.","volume":"16","author":"Pathak","year":"2014","journal-title":"Colorectal Dis"},{"issue":"11","key":"coi220091r49","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s10552-015-0663-8","article-title":"Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis.","volume":"26","author":"Woo","year":"2015","journal-title":"Cancer Causes Control"},{"key":"coi220091r50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637650","article-title":"Prognostic value of C-reactive protein, Glasgow prognostic score, and C-reactive protein-to-albumin ratio in colorectal cancer.","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"coi220091r51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4236\/wjcd.2012.21003","article-title":"The effects of EPA+DHA and aspirin on inflammatory cytokines and angiogenesis factors.","volume":"2","author":"Block","year":"2012","journal-title":"World J Cardiovasc Dis"},{"issue":"23","key":"coi220091r52","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/jnci\/djp346","article-title":"Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas.","volume":"101","author":"Ho","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"coi220091r53","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/1055-9965.EPI-14-1363","article-title":"Association between regular aspirin use and circulating markers of inflammation: a study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.","volume":"24","author":"Lang Kuhs","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"coi220091r54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1055-9965.EPI-15-0956","article-title":"Factors associated with multiple biomarkers of systemic inflammation.","volume":"25","author":"Navarro","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"coi220091r55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cyto.2014.01.003","article-title":"Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus Study).","volume":"66","author":"Vaucher","year":"2014","journal-title":"Cytokine"},{"issue":"12","key":"coi220091r56","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end.","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat Immunol"},{"issue":"1","key":"coi220091r57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00384-010-1060-0","article-title":"Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6\u2013STAT3 signaling pathway.","volume":"26","author":"Tian","year":"2011","journal-title":"Int J Colorectal Dis"},{"key":"coi220091r58","author":"Xiao","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"coi220091r59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic.","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"coi220091r60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-a\/NF-?B\/Snail pathway in cancer cell migration and invasion.","volume":"102","author":"Wu","year":"2010","journal-title":"Br J Cancer"},{"issue":"4","key":"coi220091r61","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/ajcn\/80.4.1029","article-title":"Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction.","volume":"80","author":"Lopez-Garcia","year":"2004","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"coi220091r62","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/gerona\/60.6.760","article-title":"Association between physical activity, physical performance, and inflammatory biomarkers in an elderly population: the InCHIANTI study.","volume":"60","author":"Elosua","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"coi220091r63","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v116:4","author":"McCleary","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"coi220091r64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications.","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"issue":"16","key":"coi220091r65","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1200\/JCO.2014.59.7799","article-title":"Role of physical activity and diet after colorectal cancer diagnosis.","volume":"33","author":"Van Blarigan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220091r66","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease.","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"coi220091r67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H","article-title":"TNFa and the TNF receptor superfamily: structure-function relationship(s).","volume":"50","author":"Idriss","year":"2000","journal-title":"Microsc Res Tech"},{"key":"coi220091r68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection.","volume":"9","author":"Sproston","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"coi220091r70","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2016-000550","article-title":"Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic.","volume":"4","author":"Davis","year":"2017","journal-title":"Open Heart"},{"issue":"5","key":"coi220091r71","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.amepre.2014.11.005","article-title":"Aspirin use among adults in the US: results of a national survey.","volume":"48","author":"Williams","year":"2015","journal-title":"Am J Prev Med"},{"issue":"4","key":"coi220091r72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF mutations in stage II and III colon cancer: a systematic review and meta-analysis.","volume":"114","author":"Formica","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"coi220091r73","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.ejca.2010.05.009","article-title":"Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.","volume":"46","author":"Guastadisegni","year":"2010","journal-title":"Eur J Cancer"},{"issue":"24","key":"coi220091r74","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"coi220091r75","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer.","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"coi220091r6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/B978-0-7020-6896-6.00002-8","volume-title":"Clinical Immunology","author":"Lewis","year":"2019","edition":"5th ed"},{"key":"coi220091r28","volume-title":"Statistical Analysis With Missing Data","author":"Little","year":"2019"},{"key":"coi220091r31","volume-title":"Statistical Inference","author":"Casella","year":"2002"},{"key":"coi220091r69","volume-title":"Goldfrank\u2019s Toxicologic Emergencies","author":"Holubek","year":"2010","edition":"9th ed"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2800946\/jamaoncology_cheng_2023_oi_220091_1678387696.31007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T03:08:09Z","timestamp":1728788889000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.6911","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}